xtremepicks.com: www.Xtremepicks.Com: Xtremepicks Alerts November 4, 2009 : FLML, XING, AFFY and MOCO

Xtremepicks.com Alerts include Flamel Technologies (Nasdaq: FLML), Qiao Xing Universal Telephone, Inc. (Nasdaq: XING), Affymax, Inc. (Nasdaq: AFFY) and MOCON, Inc. (Nasdaq: MOCO)

Flamel Technologies (Nasdaq:FLML) trading at $9.02 on a volume of 16,673 shares

In a press release out on November 4, Flamel Technologies Announces Licensing Agreement with Pfizer

LYON, France, Nov 04, 2009 -- Flamel Technologies (Nasdaq:FLML) today announced that Pfizer (NYSE:PFE) has exercised its option to license Flamel's Medusa(R) technology for the development of a controlled release formulation of an already-marketed therapeutic protein. Flamel will receive a further payment of $1 million pursuant to the exercise of the license; Pfizer will pay all development costs of the program, including milestone payments and royalties on any worldwide commercial sales. The program was begun in 2007 with Wyeth, which was acquired by Pfizer last month. The program leverages Flamel's ability to create controlled-release formulations of therapeutic proteins for intravenous administration.

Flamel Technologies, S.A. is a biopharmaceutical company principally engaged in the development of two unique polymer-based delivery technologies for medical applications. Micropump(R) is a controlled release and taste-masking technology for the oral administration of small molecule drugs. Flamel's Medusa technology is designed to deliver controlled-release formulations of proteins, peptides, as well as other large and small molecules. The Medusa platform is being applied to improve partners' already-marketed and novel biologics with respect to safety and efficacy, as well as with better pharmacokinetics. Medusa also offers important solutions to threshold issues such as aggregation and solubility.

Qiao Xing Universal Telephone, Inc. (Nasdaq: XING) trading at $2.12 per share on trading volume of 396,340 shares.

In a press release out on November 4, Qiao Xing Universal Telephone, Inc. Restructured Its 2006 Unsecured Convertible Notes

HUIZHOU, China, Nov 04, 2009 -- Qiao Xing Universal Telephone, Inc. (Nasdaq: XING) (the "Company") announced today that the Company has completed the restructuring of its unsecured convertible notes in the aggregate principal amount of USD26 million issued on October 31, 2006 ("the 2006 Notes").

About Qiao Xing Universal Telephone, Inc.

Qiao Xing Universal Telephone, Inc. is an emerging Chinese resources company headquartered in Huizhou, Guangdong Province. The Company was previously one of the leading players of telecommunication terminal products in China, but made the strategic decision to diversify into the resources industry in 2007. In April 2009, the Company acquired 100% equity interest in China Luxuriance Jade Company, Ltd (CLJC). CLJC, through its wholly owned Chinese subsidiaries, owns the rights to receive [0]the expected residual returns from Chifeng Haozhou Mining Co., Ltd. ("Haozhou Mining"), a large copper-molybdenum poly-metallic mining company in Inner Mongolia, China. Since then, the Company has further refined its strategy to become a pure resources company and is actively seeking additional acquisition targets in the resources industry while negotiating with potential buyers to divest its indoor phone and lower-end mobile phone business.

Affymax, Inc. (Nasdaq:AFFY) trading at $21.26 on a volume of 37,117 shares

In a press release out on November 4, Affymax(R) Reports Third Quarter 2009 Financial Results

PALO ALTO, Calif., Nov 04, 2009 -- Affymax, Inc. (Nasdaq:AFFY) today reported financial results for the third quarter ended September 30, 2009. The net loss for the third quarter of 2009 was $18.4 million compared to a net loss of $26.2 million for the third quarter of 2008.

About Affymax, Inc.

Affymax, Inc. is a biopharmaceutical company committed to developing novel drugs to improve the treatment of serious and often life-threatening conditions. Affymax's product candidate, Hematide(TM), is currently in Phase 3 clinical trials for the treatment of anemia associated with chronic renal failure. For additional information, please visit www.affymax.com.

MOCON, Inc. (Nasdaq:MOCO) trading at $8.20 on a volume of 1,000 shares

In a press release out on November 4, MOCON Announces Third Quarter Sales and Net Income

MINNEAPOLIS, Nov 04, 2009 -- MOCON, Inc. (Nasdaq:MOCO) today reported its operating results for the quarter ended September 30, 2009.

MOCON is a leading provider of detectors, instruments, systems and consulting services to research laboratories, production facilities, and quality control and safety departments in the medical, pharmaceutical, food and beverage, packaging, environmental, oil and gas and other industries worldwide. See www.mocon.com for more information.

Xtremepicks.com profiles early stage microcap and growth stocks that provide innovative products or services resulting in potentially "hyper-growth" opportunities. Often, these companies have yet to be recognized by Wall Street and the undiscovered nature of Xtremepicks.com's profile companies provide our members the opportunity to learn about these companies at their development stage, and more importantly before they possibly "turn the corner" and get exposed to a much larger investing audience.

Xtremepicks.com (www.Xtremepicks.com) has prepared all material herein based upon information believed to be reliable. The information contained herein is not guaranteed by Xtremepicks.com to be accurate, and should not be considered to be all-inclusive. Xtremepicks.com is a leading information resource for evaluating investment opportunities in small and microcap stocks. We focus on a limited number of companies in order to provide comprehensive coverage, including unique investment related features not available anywhere else on the Internet. To feature a company or to get more information, please visit us at www.Xtremepicks.com or email us at info@Xtremepicks.com Xtremepicks.coms affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event of a rise in value. Xtremepicks.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

To view full disclaimers, go to http://www.Xtremepicks.com/disclaimer.htm

CONTACT: Xtremepicks.com e-mail: Info@xtremepicks.com WWW: http://www.Xtremepicks.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

Related terms: acquisition, anemia, business, california, china, clinical, commercial, consulting, copper, drugs, email, e-mail, equity, financial results, food, france, gasoline, guangdong, investment, investment opinion, medical, mining, nasdaq, nyse, packaging, pharmaceuticals, products, profit, quality control, research, sales, technology, web